A majority of the US Supreme Court handed down a decision yesterday which draws a fuzzy line between valid patents which claim business methods and invalid ones which merely claim abstract ideas.
An amici curiae brief has been filed by a Professor of Law at Stanford Law School on behalf of 86 other professors of Law, Economics, Business and Public Policy in relation to the appropriate treatment of reverse settlement agreements.
Further to our 18 May post in relation to the FTC’s anti-trust case against Cephalon concerning the reverse settlement of a patent dispute over Provigil, a US Court of Appeals has taken the unusual step of inviting a petition to the Full Court of Appeals to consider the “difficult questions at issue and the important interests at stake” when considering reverse settlement agreements.
A US District Court has refused an application by Cephalon to dismiss a case brought against it by the FTC in relation to the settlement of a patent dispute between Cephalon and would-be generic manufacturers of Provigil (modafinil), a drug used in the treatment of sleep disorders which recorded $961 million in sales in 2009 alone.
This morning the High Court refused an application by Sanofi-Aventis for special leave to appeal a decision of the Full Court of the Federal Court which found that its patent claiming salts of the isolated enantiomer of a known racemate was invalid for want of inventive step.
The Federal Court has handed down its findings in the case brought by class action representative Mr Graeme Peterson against Merck Sharpe & Dohme in which it was alleged that Vioxx contributed to Mr Peterson’s heart attack, and that Merck had intentionally downplayed the cardiovascular risks which were associated with the drug.
The Advisory Council on Intellectual Property has released an Interim Report on Post-Grant Enforcement Strategies proposing a number of reforms, including the establishment of an IP dispute resolution centre to provide opinions in relation to validity and infringement issues, and public access to information in relation to patent related Court proceedings.